Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer

被引：28

作者：

Hayata, Keiji ^{[1
]}

Ojima, Toshiyasu ^{[1
]}

Nakamori, Mikihito ^{[1
]}

Nakamura, Masaki ^{[1
]}

Katsuda, Masahiro ^{[1
]}

Kitadani, Junya ^{[1
]}

Takeuchi, Akihiro ^{[1
]}

Tabata, Hirotaka ^{[1
]}

Maruoka, Shinpei ^{[1
]}

Yamaue, Hiroki ^{[1
]}

机构：

[1] Wakayama Med Univ, Sch Med, Dept Surg 2, 811-1 Kimiidera, Wakayama 6418510, Japan

来源：

ANTICANCER RESEARCH | 2018年 / 38卷 / 09期

基金：

日本学术振兴会;

关键词：

Neoadjuvant chemotherapy; esophageal cancer; docetaxel; cisplatin; S-1; SQUAMOUS-CELL CARCINOMA; PREOPERATIVE CHEMOTHERAPY; PHASE-II; GASTRIC-CANCER; 5-FLUOROURACIL; FLUOROURACIL; CLASSIFICATION; THERAPY; TRIAL; PART;

D O I：

10.21873/anticanres.12852

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Although the efficacy is limited, standard therapy for Stage II/III esophageal cancer in Japan includes neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil. A phase II trial was conducted on patients with resectable advanced esophageal cancer obtaining neoadjuvant chemotherapy with docetaxel, cisplatin plus S-1 (DCS). Patients and Methods: A total of 40 patients were enrolled, each treated by the following DCS regimen: docetaxel 40 mg/m(2), cisplatin 60 mg/m(2) on day 1, and S-1 80 mg/m(2) on days 1-14, repeated every four weeks, for a maximum of three cycles. Results: Clinical response rate was 76% and the pathological response rate (Grade 2/3) was 33%. Hematological toxicities of Grade 3/4 were leukopenia 50%, neutropenia 68%, and febrile neutropenia 18%. Conclusion: Neoadjuvant chemotherapy with DCS is a feasible therapeutic strategy for patients with advanced thoracic esophageal squamous cell carcinoma.

引用

页码：5267 / 5273

页数：7

共 20 条

[1] PROLONGED CHEMOTHERAPY FOR LOCALIZED SQUAMOUS CARCINOMA OF THE ESOPHAGUS [J].

AJANI, JA ;

RYAN, B ;

RICH, TA ;

MCMURTREY, M ;

ROTH, JA ;

DECARO, L ;

LEVIN, B ;

MOUNTAIN, C .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :880-884

[2] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Hofheinz, Ralf D. ;

Pauligk, Claudia ;

Kopp, Hans-Georg ;

Haag, Georg Martin ;

Luley, Kim Barbara ;

Meiler, Johannes ;

Homann, Nils ;

Lorenzen, Sylvie ;

Schmalenberg, Harald ;

Probst, Stephan ;

Koenigsmann, Michael ;

Egger, Matthias ;

Prasnikar, Nicole ;

Caca, Karel ;

Trojan, Joerg ;

Martens, Uwe M. ;

Block, Andreas ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Clemens, Michael ;

Illerhaus, Gerald ;

Zirlik, Katja ;

Behringer, Dirk M. ;

Schmiegel, Wolff ;

Pohl, Michael ;

Heike, Michael ;

Ronellenfitsch, Ulrich ;

Schuler, Martin ;

Bechstein, Wolf O. ;

Koenigsrainer, Alfred ;

Gaiser, Timo ;

Schirmacher, Peter ;

Hozaeel, Wael ;

Reichart, Alexander ;

Goetze, Thorsten O. ;

Sievert, Mark ;

Jaeger, Elke ;

Moenig, Stefan ;

Tannapfel, Andrea .

LANCET ONCOLOGY, 2016, 17 (12) :1697-1708

[3] A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) [J].

Ando, Nobutoshi ;

Kato, Hoichi ;

Igaki, Hiroyasu ;

Shinoda, Masayuki ;

Ozawa, Soji ;

Shimizu, Hideaki ;

Nakamura, Tsutomu ;

Yabusaki, Hiroshi ;

Aoyama, Norio ;

Kurita, Akira ;

Ikeda, Kenichiro ;

Kanda, Tatsuo ;

Tsujinaka, Toshimasa ;

Nakamura, Kenichi ;

Fukuda, Haruhiko .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :68-74

[4]

[Anonymous], 2011, AJCC CANC STAGING HD

[5] Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].

Dindo, D ;

Demartines, N ;

Clavien, PA .

ANNALS OF SURGERY, 2004, 240 (02) :205-213

[6] Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma [J].

Hara, Hiroki ;

Tahara, Makoto ;

Daiko, Hiroyuki ;

Kato, Ken ;

Igaki, Hiroyasu ;

Kadowaki, Shigenori ;

Tanaka, Yoichi ;

Hamamoto, Yasuo ;

Matsushita, Hisayuki ;

Nagase, Michitaka ;

Hosoya, Yoshinori .

CANCER SCIENCE, 2013, 104 (11) :1455-1460

[7] Circular stapling versus triangulating stapling for the cervical esophagogastric anastomosis after esophagectomy in patients with thoracic esophageal cancer: A prospective, randomized, controlled trial [J].

Hayata, Keiji ;

Nakamori, Mikihito ;

Nakamura, Masaki ;

Ojima, Toshiyasu ;

Iwahashi, Makoto ;

Katsuda, Masahiro ;

Tsuji, Toshiaki ;

Kato, Tomoya ;

Kitadani, Jyunya ;

Takeuchi, Akihiro ;

Tabata, Hirotaka ;

Yamaue, Hiroki .

SURGERY, 2017, 162 (01) :131-138

[8]

IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172

[9] A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002 [J].

Ito, Seiji ;

Sano, Takeshi ;

Mizusawa, Junki ;

Takahari, Daisuke ;

Katayama, Hiroshi ;

Katai, Hitoshi ;

Kawashima, Yoshiyuki ;

Kinoshita, Takahiro ;

Terashima, Masanori ;

Nashimoto, Atsushi ;

Nakamori, Mikihito ;

Onaya, Hiroaki ;

Sasako, Mitsuru .

GASTRIC CANCER, 2017, 20 (02) :322-331

[10] Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study) [J].

Nakamura, Kenichi ;

Kato, Ken ;

Igaki, Hiroyasu ;

Ito, Yoshinori ;

Mizusawa, Junki ;

Ando, Nobutoshi ;

Udagawa, Harushi ;

Tsubosa, Yasuhiro ;

Daiko, Hiroyuki ;

Hironaka, Shuichi ;

Fukuda, Haruhiko ;

Kitagawa, Yuko .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (07) :752-755

← 1 2 →